SWM
NVCT icon

Spire Wealth Management’s Nuvectis Pharma NVCT Stock Holding History

Spire Wealth Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300
Closed -$2.32K – 2329
2026
Q1 		$2.32K Hold
300
– – ﹤0.01% 2016
2025
Q4 		$2.27K Buy
+300
New +$1.96K ﹤0.01% 2073

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Spire Wealth Management's NVCT Position: Q2 2026 in Review

Spire Wealth Management sold out of Nuvectis Pharma (NVCT) in Q2 2026, closing a stake of 300 shares — an estimated $2.32K sold.

Spire Wealth Management first reported a position in NVCT in Q4 2025 and held it in 2 quarters. The position peaked at $2.32K in Q1 2026. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Spire Wealth Management reported no remaining Nuvectis Pharma position as of Q2 2026 after selling out during the quarter.
  • Spire Wealth Management sold 300 Nuvectis Pharma shares in Q2 2026, an estimated $2.32K.
  • Spire Wealth Management first reported a position in Nuvectis Pharma in Q4 2025 and held it in 2 quarters.
  • Spire Wealth Management's Nuvectis Pharma position peaked at $2.32K in Q1 2026.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.